Retinoic Acid Receptor β2 Agonists Restore Glycemic Control In Diabetes and Reduce Steatosis.

CONCLUSIONS: Collectively, our data show that orally active, rapidly acting, high affinity pharmacological agonists for RARβ2 improve the diabetic phenotype while reducing lipid levels in key insulin target tissues. We suggest that RARβ2 agonists should be useful drugs for T2D therapy and for treatment of hepatic steatosis. PMID: 26462866 [PubMed - as supplied by publisher]
Source: Diabetes Metab - Category: Endocrinology Authors: Tags: Diabetes Obes Metab Source Type: research